Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.

source https://finance.yahoo.com/news/pfizer-top-drugmaker-time-buy-155703745.html?.tsrc=rss